|
|||||
|
|
A Phase II Expansion Study of Vorinostat in Combination With Idarubicin and Cytarabine for Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations |
|
| Affiliation: | 1. Department of Laboratory Hematology, University Health Network, Toronto, Ontario, Canada M5G 2C4;2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A1;3. Department of Pathology, University Health Network, Toronto, Ontario, Canada M5G 2C4;4. Department of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada M5G 2C4 |
| Abstract: | |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |